Abstract 100: Interleukin 1 receptor type II upregulates MMP1 expression and increases motility of keratinocytes cells

Abstract

Abstract We have shown that long-term exposure to low doses of inorganic arsenite (iAs) induced malignant transformation of non-tumorigenic human keratinocytes, HaCaT cells. We further demonstrated that enhanced expression of a decoy type II receptor of interleukin-1 (IL1R2) in transformed keratinocytes mediated through IL-6 and VEGFR to increase the migration and invasion activities, indicating the oncogenic potential of IL1R2. In this present study, we further explored how IL1R2 enhances the cell motility in human keratinocytes. As described earlier, long-term and low dose iAs (0, 0.5 and 1 μM) exposed HaCaT cells were designated as HaCaT A0, A1 and A2 cells, respectively. The tumorigenic cell line, T4R2, was derived from the tumor in mice implanted with HaCaT A2 cells. By growing HaCaT A0, A1, A2 and T4R2 cells on an organotypic culture system using basal medium, we found that T4R2 cells formed multilayered morphology. By aid of siRNA and ectopic expression techniques, we further demonstrated that increased expression of IL1R2 in T4R2 cells was associated with increased matrix metalloproteinase-1 (MMP1) and enhanced cell motility. The roles of MMP1 on supporting the organotypic growth of T4R2 cells were confirmed by using the stably MMP1-silenced T4R2 cells (T4R2-shMMP1). The cell motility of T4R2-shMMP1 cells was also significantly reduced. Furthermore, IL1R2-induced MMP1 upregulation was remarkably inhibited by inhibitors of MAPK/ERK signaling. Our present results revealed that MMP1 was one of downstream targets of IL1R2 which plays a crucial role on the progression of malignancy. Therefore, IL1R2 may be a target for cancer intervention. Citation Format: Hsiu-Hua Wang, Te-Chang Lee. Interleukin 1 receptor type II upregulates MMP1 expression and increases motility of keratinocytes cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 100.